{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:15:30Z","timestamp":1740147330789,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Nintedanib was approved for the treatment of scleroderma and scleroderma-related interstitial lung disease, as it decrease the forced expiratory volume.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 48-year-old Asian female patient with systemic scleroderma 6\u00a0years ago developed breathlessness, nausea, heart palpation, and sudden severe occipital headache over the preceding week. She was receiving aspirin 81\u00a0mg\/day and amlodipine 5\u00a0mg\/day. Her diagnosis was diffuse scleroderma with pulmonary hypertension, interstitial lung involvement, and renal crisis. The modified Rodnan score was 18. We begin captopril at a dose of 12.5\u00a0mg, progressively escalating to 200\u00a0mg\/day, and oral nintedanib was started at 150\u00a0mg. A total of 12\u00a0months after initiation of treatment, the patient\u2019s kidney function was normal. The pulmonary function tests improved. The modified Rodnan score was reduced to 10. We did not encounter any side effects in our case due to nintedanib treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Treatment with nintedanib is crucial for slowing lung function decline. Diarrhea was the most common adverse event. Scleroderma renal crisis occurs in 10% of patients and typically presents with an abrupt onset of hypertension and kidney failure. The optimal antihypertensive agent for scleroderma renal crisis is an ACE inhibitor. The mainstay of therapy in scleroderma renal crisis has been shown to improve or stabilize renal function in approximately 70% of patients and improve survival in nearly 80% at 1\u00a0year. Nintedanib may be effective, and fairly safe to use. Further exploration is anticipated to advance a new period of systemic sclerosis treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-024-04433-2","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T01:26:32Z","timestamp":1708651592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nintedanib in systemic sclerosis treatment: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Maysoun","family":"Kudsi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6148-4699","authenticated-orcid":false,"given":"Raghad","family":"Tarcha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naram","family":"Khalayli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"4433_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08929-x","author":"MG Lazzaroni","year":"2022","unstructured":"Lazzaroni MG, Piantoni S, Angeli F, et al. A narrative review of pathogenetic and histopathologic aspects, epidemiology, classification systems, and disease outcome measures in systemic sclerosis. Clinic Rev Allerg Immunol. 2022. https:\/\/doi.org\/10.1007\/s12016-022-08929-x.","journal-title":"Clinic Rev Allerg Immunol"},{"issue":"15","key":"4433_CR2","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.3390\/jcm11154631","volume":"11","author":"S Ebata","year":"2022","unstructured":"Ebata S, et al. New era in systemic sclerosis treatment: recently approved therapeutics. J Clin Med. 2022;11(15):4631. https:\/\/doi.org\/10.3390\/jcm11154631.","journal-title":"J Clin Med"},{"key":"4433_CR3","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1136\/annrheumdis-2018-213455","volume":"78","author":"W Wu","year":"2019","unstructured":"Wu W, Jordan S, Graf N, de Oliveira Pena J, Curram J, Allanore Y, Matucci-Cerinic M, Pope JE, Denton CP, Khanna D, et al. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. Ann Rheum Dis. 2019;78:648\u201356. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213455.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4433_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102730","volume":"20","author":"C Varrica","year":"2021","unstructured":"Varrica C, et al. Targeted delivery in scleroderma fibrosis. Autoimmun Rev. 2021;20(2): 102730. https:\/\/doi.org\/10.1016\/j.autrev.2020.102730.","journal-title":"Autoimmun Rev"},{"key":"4433_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13075-020-2140-3","volume":"22","author":"S Panopoulos","year":"2020","unstructured":"Panopoulos S, Chatzidionysiou \u039a, Tektonidou MG, et al. Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort. Arthritis Res Ther. 2020;22:56. https:\/\/doi.org\/10.1186\/s13075-020-2140-3.","journal-title":"Arthritis Res Ther"},{"key":"4433_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B, Mayes MD, Nash RA, Crofford LJ, Eggleston B, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378:35\u201347. https:\/\/doi.org\/10.1056\/NEJMoa1703327.","journal-title":"N Engl J Med"},{"key":"4433_CR7","doi-asserted-by":"publisher","DOI":"10.5301\/jsrd.5000267","author":"D Khanna","year":"2017","unstructured":"Khanna D, et al. Tocilizumab treatment of patients with systemic sclerosis: clinical data. SAGE J. 2017. https:\/\/doi.org\/10.5301\/jsrd.5000267.","journal-title":"SAGE J"},{"issue":"6","key":"4433_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/1744666X.2020.1777857","volume":"16","author":"Y Yamasaki","year":"2020","unstructured":"Yamasaki Y, Kuwana M. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. Expert Rev Clin Immunol. 2020;16(6):547\u201360. https:\/\/doi.org\/10.1080\/1744666X.2020.1777857.","journal-title":"Expert Rev Clin Immunol"},{"key":"4433_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2020.101941","volume":"64","author":"C Landi","year":"2020","unstructured":"Landi C, Carleo A, Vantaggiato L, Bergantini L, d\u2019Alessandro M, Cameli P, Sebastiani G, Dotta F, Bargagli E. Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study. Pulm Pharmacol Ther. 2020;64: 101941. https:\/\/doi.org\/10.1016\/j.pupt.2020.101941. (Epub 2020 Sep 5).","journal-title":"Pulm Pharmacol Ther"},{"key":"4433_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109409.ISSN1567-5769","volume":"113","author":"W Yang","year":"2022","unstructured":"Yang W, Pan L, Cheng Y, Wu X, Tang B, Zhu H, Zhang M, Zhang Y. Nintedanib alleviates pulmonary fibrosis in vitro and in vivo by inhibiting the FAK\/ERK\/S100A4 signalling pathway. Int Immunopharmacol. 2022;113: 109409. https:\/\/doi.org\/10.1016\/j.intimp.2022.109409.ISSN1567-5769.","journal-title":"Int Immunopharmacol"},{"key":"4433_CR11","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65:2737\u201347. https:\/\/doi.org\/10.1002\/art.38098.","journal-title":"Arthritis Rheum"},{"key":"4433_CR12","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ijsu.2020.10.034","volume":"84","author":"RA Agha","year":"2020","unstructured":"Agha RA, Franchi T, Sohrabi C, et al. The SCARE 2020 Guideline: updating Consensus Surgical Case Report (SCARE) Guidelines. Int J Surg. 2020;84:226\u201330.","journal-title":"Int J Surg"},{"key":"4433_CR13","unstructured":"http:\/\/www.researchregistery.com."},{"issue":"3","key":"4433_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2217\/imt.13.173","volume":"6","author":"G Murdaca","year":"2014","unstructured":"Murdaca G, Span\u00f2 F, Contatore M, Guastalla A, Puppo F. Potential use of TNF-\u03b1 inhibitors in systemic sclerosis. Immunotherapy. 2014;6(3):283\u20139. https:\/\/doi.org\/10.2217\/imt.13.173.","journal-title":"Immunotherapy"},{"issue":"9","key":"4433_CR15","doi-asserted-by":"publisher","first-page":"7849","DOI":"10.3390\/ijms24097849","volume":"24","author":"F Amati","year":"2023","unstructured":"Amati F, Stainer A, Polelli V, Mantero M, Gramegna A, Blasi F, Aliberti S. Efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis: a systematic review. Int J Mol Sci. 2023;24(9):7849. https:\/\/doi.org\/10.3390\/ijms24097849.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4433_CR16","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12890-021-01783-1","volume":"21","author":"JP Finnerty","year":"2021","unstructured":"Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm Med. 2021;21(1):411. https:\/\/doi.org\/10.1186\/s12890-021-01783-1.","journal-title":"BMC Pulm Med"},{"key":"4433_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13075-021-02536-5","volume":"23","author":"C Campochiaro","year":"2021","unstructured":"Campochiaro C, Allanore Y. An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3\u00a0years. Arthritis Res Ther. 2021;23:155. https:\/\/doi.org\/10.1186\/s13075-021-02536-5.","journal-title":"Arthritis Res Ther"},{"key":"4433_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207109","author":"J Huang","year":"2016","unstructured":"Huang J, Beyer C, Palumbo-Zerr K, Zhang Y, Ramming A, Distler A, Gelse K, Distler O, Schett G, Wollin L, Distler JHW. Basic and translational research: extended report: nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis. 2016. https:\/\/doi.org\/10.1136\/annrheumdis-2014-207109.","journal-title":"Ann Rheum Dis"},{"key":"4433_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222564","author":"A Azuma","year":"2022","unstructured":"Azuma A, Mayes MD, Gahlemann M, James A, Kohlbrenner V, Alves M, Khanna D, Highland KB, on behalf of the SENSCIS-ON trial investigators. Systemicsclerosis. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/ard-2022-222564.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"4433_CR20","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3390\/jpm12071123","volume":"12","author":"F Reggiani","year":"2022","unstructured":"Reggiani F, Moroni G, Ponticelli C. Kidney involvement in systemic sclerosis. J Pers Med. 2022;12(7):1123. https:\/\/doi.org\/10.3390\/jpm12071123.","journal-title":"J Pers Med"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04433-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-024-04433-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04433-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T01:26:43Z","timestamp":1708651603000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-024-04433-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4433"],"URL":"https:\/\/doi.org\/10.1186\/s13256-024-04433-2","relation":{},"ISSN":["1752-1947"],"issn-type":[{"type":"electronic","value":"1752-1947"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"1 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the national research committee and with the 1964 Helsinki Declaration.Our case was approved by the Ethical Committee of Faculty of Medicine (N;H;3415,2022), Damascus University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No potential conflict of interest relevant to this article was reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}